aibioFEMY FEMASYS INC
FEMASYS INC (FEMY) news
FEMASYS INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FEMY, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest FEMASYS INC news
We have not published a story on FEMASYS INC yet. When there is news, it will appear here.
FEMASYS INC annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.3 million | $1.6 million |
| Research and development | $7.6 million | $8.2 million |
| Net income (loss) | -$18.6 million | -$18.8 million |
| Cash from operations | -$18.7 million | -$19.4 million |
| Cash and equivalents | $9.3 million | $3.5 million |
Questions about FEMASYS INC
What is the ticker symbol of FEMASYS INC?
FEMASYS INC trades under the ticker FEMY on NASDAQ.
Where is FEMASYS INC listed?
FEMASYS INC is listed on NASDAQ.
Which country or territory is FEMASYS INC listed under?
Our directory records FEMASYS INC under United States.
Does aibio.space cover FEMASYS INC?
aibio.space lists FEMASYS INC among 2,820 public biotech companies and publishes its news here as stories appear.
What was FEMASYS INC's revenue last year?
$2.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is FEMASYS INC profitable?
FEMASYS INC reported a net loss of $18.6 million for the fiscal year ended Dec 31, 2025, and used $18.7 million of cash in operations, per its annual report to the SEC.
How much does FEMASYS INC spend on research and development?
$7.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does FEMASYS INC have?
$1.4 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: FEMASYS INC
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 7.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Stock chart
Listing details
- Company
- FEMASYS INC
- Ticker
- FEMY
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction